Skip to main content
. 2024 Mar 11;19(2):237–249. doi: 10.1007/s11523-024-01039-y

Fig. 3.

Fig. 3

a EFS and b OS in AML1/ETO-positive patients treated with frontline VEN/HMA according to KIT mutation status. AML acute myeloid leukemia, EFS event-free survival, HMA hypomethylating agent, OS overall survival, VEN venetoclax